Primary Sclerosing Cholangitis (PSC)

Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.

Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.

PUBLIC PAGE
Jun 22 7:00am

Active Clinical Trials for Primary Sclerosing Cholangitis at Mayo Clinic

By Konstantinos N. Lazaridis, M.D., @klazaridis

shutterstock_1073659442

Clinical Trials are a fundamental aspect of our research and clinical efforts for Primary Sclerosing Cholangitis (PSC) at Mayo Clinic. At the present time, we have four clinical trials for patients with PSC open for enrollment, listed below:

Ongoing Clinical Trials

Investigation of Vidofludimus Calcium for PSC.  Open label study, 6 month treatment period.  For more details please go to: ClinicalTrials.gov Identifier: NCT03722576

Investigation of Cilofexor (an FXR agonist) for PSC.  Randomized, placebo-controlled study, 96 week treatment period. For more details please go to: ClinicalTrials.gov Identifier: NCT03890120

A Prospective, Randomized, Multi-Centered, Placebo-Controlled Clinical Trial of Oral Vancomycin in Adults with Primary Sclerosing Cholangitis

This phase II, randomized, placebo-controlled clinical trial is designed to examine the safety, tolerability and efficacy of daily dosing (over an 18-month period) with oral vancomycin, using a stepped-up dosing strategy with three increasing doses, on the clinical course, and the progression of PSC, and to compare the treated patients with those on placebo.

Multi-omics of Primary Sclerosing Cholangitis

This translational study seeks to generate the first, multi-omics and comprehensive clinical data resource for PSC. The study aims to define the bigger-picture cellular networks and gene-environment interactions driving PSC by integrating several layers of -omics data. In so doing, we will identify molecular disease signatures, including environmental toxins, metabolism-related chemicals and gut bacteria, unique to PSC patients.

For questions please call Mr. Mitchell Clayton (Clinical research coordinator) 507-284-2698.

Please login or register to post a reply.

Invite Others

Send an email to invite people you know to join the Primary Sclerosing Cholangitis (PSC) page.

Please login or register to send an invite.